Trials / Completed
CompletedNCT00571727
Long-Term Treatment With rhIGF-1 in GHIS
A Study of Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS)
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 2 Years – 21 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to evaluate the long-term safety and effectiveness of mecasermin (the study drug) in children with growth failure due to severe Primary insulin-like growth factor-1 deficiency (Primary IGFD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mecasermin | injections BID of rhIGF-1, mecasermin |
Timeline
- Start date
- 1991-05-20
- Primary completion
- 2011-12-15
- Completion
- 2011-12-15
- First posted
- 2007-12-12
- Last updated
- 2023-07-06
- Results posted
- 2023-07-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00571727. Inclusion in this directory is not an endorsement.